Robert W. Baird Cuts Danaher (NYSE:DHR) Price Target to $309.00

Danaher (NYSE:DHRGet Rating) had its price target dropped by research analysts at Robert W. Baird from $321.00 to $309.00 in a research report issued to clients and investors on Wednesday, The Fly reports. Robert W. Baird’s price objective would suggest a potential upside of 13.78% from the company’s current price.

Several other equities analysts have also weighed in on DHR. Benchmark lowered shares of Danaher from a “buy” rating to a “hold” rating and set a $325.00 price target for the company. in a research report on Monday, October 24th. Royal Bank of Canada dropped their price objective on shares of Danaher from $318.00 to $302.00 and set an “outperform” rating on the stock in a report on Friday, October 21st. JPMorgan Chase & Co. dropped their price objective on shares of Danaher from $350.00 to $315.00 and set an “overweight” rating on the stock in a report on Friday, October 21st. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Danaher in a report on Tuesday, December 13th. They set a “buy” rating and a $310.00 price objective on the stock. Finally, StockNews.com raised shares of Danaher from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Three analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and a consensus price target of $309.54.

Danaher Price Performance

DHR opened at $271.58 on Wednesday. The firm has a market cap of $197.70 billion, a P/E ratio of 30.01, a PEG ratio of 2.23 and a beta of 0.82. The firm has a 50-day moving average of $266.13 and a 200 day moving average of $268.98. The company has a debt-to-equity ratio of 0.41, a quick ratio of 1.38 and a current ratio of 1.78. Danaher has a fifty-two week low of $233.71 and a fifty-two week high of $303.82.

Danaher (NYSE:DHRGet Rating) last posted its quarterly earnings results on Tuesday, January 24th. The conglomerate reported $2.87 earnings per share for the quarter, beating the consensus estimate of $2.45 by $0.42. The company had revenue of $8.37 billion during the quarter, compared to analyst estimates of $7.90 billion. Danaher had a net margin of 21.65% and a return on equity of 18.33%. The firm’s revenue for the quarter was up 2.7% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.69 earnings per share. On average, research analysts expect that Danaher will post 10.55 EPS for the current year.

Insider Buying and Selling

In other news, SVP Georgeann Couchara sold 1,884 shares of the firm’s stock in a transaction that occurred on Tuesday, November 15th. The shares were sold at an average price of $271.61, for a total value of $511,713.24. Following the transaction, the senior vice president now owns 2,588 shares in the company, valued at $702,926.68. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, EVP Jennifer Honeycutt sold 8,211 shares of the firm’s stock in a transaction on Thursday, November 10th. The stock was sold at an average price of $265.00, for a total value of $2,175,915.00. Following the completion of the sale, the executive vice president now owns 7,162 shares of the company’s stock, valued at $1,897,930. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 1,884 shares of the firm’s stock in a transaction on Tuesday, November 15th. The stock was sold at an average price of $271.61, for a total value of $511,713.24. Following the completion of the sale, the senior vice president now directly owns 2,588 shares of the company’s stock, valued at approximately $702,926.68. The disclosure for this sale can be found here. Over the last three months, insiders have sold 38,538 shares of company stock worth $10,424,284. Insiders own 11.20% of the company’s stock.

Institutional Trading of Danaher

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Stonegate Investment Group LLC lifted its position in Danaher by 1.3% during the fourth quarter. Stonegate Investment Group LLC now owns 179,490 shares of the conglomerate’s stock valued at $47,640,000 after buying an additional 2,216 shares during the period. Madison Wealth Partners Inc lifted its position in Danaher by 0.7% during the fourth quarter. Madison Wealth Partners Inc now owns 5,284 shares of the conglomerate’s stock valued at $1,402,000 after buying an additional 38 shares during the period. Sigma Planning Corp lifted its position in Danaher by 9.5% during the fourth quarter. Sigma Planning Corp now owns 8,621 shares of the conglomerate’s stock valued at $2,288,000 after buying an additional 746 shares during the period. Aaron Wealth Advisors LLC lifted its position in Danaher by 16.4% during the fourth quarter. Aaron Wealth Advisors LLC now owns 22,964 shares of the conglomerate’s stock valued at $6,095,000 after buying an additional 3,236 shares during the period. Finally, Koshinski Asset Management Inc. lifted its position in Danaher by 20.3% during the fourth quarter. Koshinski Asset Management Inc. now owns 978 shares of the conglomerate’s stock valued at $260,000 after buying an additional 165 shares during the period. Hedge funds and other institutional investors own 77.26% of the company’s stock.

About Danaher

(Get Rating)

Danaher Corp. operates as a medical company, which designs, manufactures, and markets professional, medical, industrial, and commercial products and services. It operates through the following segments: Life Sciences, Diagnostics, and Environmental & Applied Solutions. The Life Sciences segment offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, to understand the causes of disease, identify new therapies and test new drugs and vaccines.

Featured Stories

The Fly logo

Analyst Recommendations for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.